-
Biopharmaceonceons with volume procurement approaching
Time of Update: 2021-03-07
that they should be harvested", and the next day (1 At a regular briefing on State Council policy held on September 29, the head of the Health Insurance Bureau further stressed that "there are differences in the quality evaluation methods of generic
-
Review of the EU 2020 PRIME Priority Medicines Program
Time of Update: 2021-03-07
to be reviewed under the EMA's accelerated evaluation mechanism. this means that fast tracks are not established and it is not uncommon for products through PRIME to be reviewed within the standard time range. 84 determinations have been
-
Five years later, 60% of patients are still in remission for the long-term effects of CAR-T therapy
Time of Update: 2021-03-07
60% of patients with B-cell lymphoma treated with Kymriah are still in remission after 5 years of treatment.
-
A non-"biological" man who had a biological child sued the hospital for compensation of 300,000
Time of Update: 2021-03-07
technology, refers to married couples borrowing modern biotechnology, through unnatural sexual pregnancy of children. , 11 January 2021, the Office of the National Health Council issued the Guidelines for the Application of Human Assisted Reproductive
-
Will Chinese medicine be a good business?
Time of Update: 2021-03-07
, the clinical trial of the drug has data or high-quality Chinese medicine human experience evidence shows efficacy and can predict its clinical value, it may be approved with conditions. Amend the Regulations on the Protection of Chinese Medicine Species
-
2020 CRO average net profit industry first performance decline only three of the highest ...
Time of Update: 2021-03-07
of innovative drugs and medical devices, of which, in the NMPA, FDA innovative drug IND stage has more than 40, in the clinical stage of more than 20, is bound to increase. , with the completion of a portion of CDMO production capacity at a later stage
-
The FDA has accepted a new application from BRUKINSA (Zanubrutinib) for the treatment of Waldenström globulinemia
Time of Update: 2021-02-26
The U.S. Food and Drug Administration (FDA) has accepted an application from BRUKINSA (zanubrutinib) for a new drug (sNDA) to treat adult patients with Waldenström globulinemia (WM), the company announced today.
-
Nat Commun: Placebo controlled trial: Fecal microbiome transplantation to treat HIV
Time of Update: 2021-02-26
researchers report that fecal microbiome transplantation (FMT) is safe, has nothing to do with serious adverse events, and can reduce HIV-related microbiome disorders.
-
Cancer Discov: Venetoclax and Navitoclax, chemotherapy to treat relapse/resuscable acute lymphoblastic leukemia and lymphocytic lymphoma
Time of Update: 2021-02-26
. results showed that a total of 47 patients were treated in the study. Venotclax is recommended for adult patients with a phase II dose of 50 mg and 25 mg for patients weighing less than 45 kg. safety findings are delays
-
BMC Gastroenterology: Angiogen 2 can predict the degree of hemangiogenic and fibrosis in patients with hepatitis C
Time of Update: 2021-02-26
as by inhibiting the proliferation of tumor cells through Raf-mediated pathogens and the subject tyrosine kinase. reported that elevated levels of angiogenesin (ANGP)-2 in the blood of patients with chronic hepatitis C (CHC) were associated with fibrosis
-
AP-T: Comparison of direct oral anticoagulants and vitamin K antagonists in the risk of bleeding in the upper digestive tract
Time of Update: 2021-02-26
in order to compare the effects and side effects of new drugs and huafalin, this study analyzed the epidemiology and outcome of upper digestive tract bleeding (UGIB) caused by oral anticoagulant therapy.
-
JAHA: Plate plate rest therapy in patients with acute coronary artery syndrome who received coronary artery bridge
Time of Update: 2021-02-26
meta-analysis, the researchers compared patients with coronary arterial bridge surgery who had received more effective antiplate plateplate suppression strategies and less effective plateplate suppression strategies, respectively.
-
Blood: Results of clinical trials of BAX 335 gene therapy for type B haemophilia
Time of Update: 2021-02-25
human F9 genes into liver cells. report the results of a new study, "BAX 335 hemophilia gene therapy clinical trial results: potential impact of CpG sequences on gene expression", published recently in the journal Blood. BAX 335 Expression
-
JCO: The treatment of rhonamide combined with R-CHOP can prolong the survival of patients with untreated diffuse large B-cell lymphoma
Time of Update: 2021-02-25
For untreated patients with diffuse large B-cell lymphoma (DLBCL) (including COO and ABC-DLBCL subtypes), the Synadamic Unilidoxi monoantigen-cyclophosphamide-dorobi-star-changchun-neo-alkali-pernisson (R-CHOP) program (R2CHOP) can extend its lifetime.
-
Blood: The efficacy and safety of Flotetuzumab as a remedial immunotherapy for incurable AML patients
Time of Update: 2021-02-25
about 50% of patients with acute myeloid leukemia (AML) do not respond to induction therapy (primary induced failure (PIF)) or relapse within 6 months (early recurrence (ER).
-
Nature Sub-Journal: In-depth analysis of the global patent landscape for CAR-T therapy
Time of Update: 2021-02-25
a stronger ability to locate and attack tumor cells than ordinary T-cells. 2017, the U.S. Food and Drug Administration (FDA) approved two CAR-T cell therapies, Kymria and Yescarta, a milestone in the field of oncology immunology. The U.S. Centers
-
Seven years in hospital 22 times, heavy "re-impairment" finally cured! The sick friend was grateful and donated money to convey love
Time of Update: 2021-02-25
blood cells. after the standard anti-thymus cell immunoglobulin strong immunosuppression and then cyclosporine treatment, consciously improved symptoms, returned to Ji'an home. thought the condition improved steadily, but in early 2015
-
Dig Dis Sci: Serum globulin is associated with endoscopic results and mucous membrane healing in patients with japanese ulcerative colitis
Time of Update: 2021-02-25
This study found a significant positive correlation between serum globulin and endoscopic activity in patients with ulcerative colitis, and significantly negative correlation with mucosal healing, especially in patients with low C-reactive proteins.
-
J Clin Oncol:R-CHOP program plus lynamine can further improve prognostics in newly diagnosed DLBCL patients
Time of Update: 2021-02-25
in this trial, newly diagnosed International Prognostic Index (IPI) ≥2, ECOG Performance Status≤2 of phase II large block-IV DLBCL patients were randomly assigned to the R2CHOP group and R-CHOP group for a total of 6 cycles.
-
J Clin Oncol: Eprenetapopt combined with Aza cytosine to treat TP53 mutant MDS and AML
Time of Update: 2021-02-24
Regardless of the treatment, the prognostics of TP53 mutation (TP53m) bone marrow prognostic abnormal syndrome (MDS) and acute myeloid leukemia (AML) were very poor, with only 40% remission rate (full remission rate of 20%) for Azatide (AZA
